Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Granisetron Patch Bioequivalence and Adhesion Study
NCT05027646Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of granisetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Kyowa Kirin. Primary endpoints: Area under the plasma concentration versus time curve AUC (0-t) at 6 months, Area under the plasma concentration versus time curve AUC (0-inf) at 6 months and 4 more. Started Jul 2021; status: completed.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT05027646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027646.